MML Investors Services
BIO icon

MML Investors Services’s Bio-Rad Laboratories Class A BIO Stock Holding History

MML Investors Services’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.87M Buy
9,758
+1,816
+23% +$515K 0.01% 1313
2026
Q1 		$2.21M Sell
7,942
-2,483
-24% -$715K 0.01% 1258
2025
Q4 		$3.16M Sell
10,425
-41
-0.4% -$12.8K 0.01% 1123
2025
Q3 		$2.93M Sell
10,466
-321
-3% -$87.4K 0.01% 1112
2025
Q2 		$2.6M Sell
10,787
-6
-0.1% -$1.42K 0.01% 1120
2025
Q1 		$2.63M Buy
10,793
+133
+1% +$40K 0.01% 1036
2024
Q4 		$3.5M Buy
10,660
+5,299
+99% +$1.8M 0.01% 857
2024
Q3 		$1.79M Buy
5,361
+159
+3% +$50.5K 0.01% 1151
2024
Q2 		$1.42M Sell
5,202
-2,362
-31% -$687K 0.01% 1205
2024
Q1 		$2.62M Buy
7,564
+1,290
+21% +$424K 0.01% 921
2023
Q4 		$2.03M Sell
6,274
-3,811
-38% -$1.19M 0.01% 985
2023
Q3 		$3.62M Sell
10,085
-282
-3% -$109K 0.02% 665
2023
Q2 		$3.93M Buy
+10,367
New +$4.22M 0.02% 629
2023
Q1 		– Sell
-8,487
Closed -$3.57M – 2093
2022
Q4 		$3.57M Buy
8,487
+528
+7% +$213K 0.02% 613
2022
Q3 		$3.32M Buy
7,959
+944
+13% +$471K 0.03% 568
2022
Q2 		$3.47M Buy
7,015
+590
+9% +$307K 0.03% 537
2022
Q1 		$3.62M Buy
6,425
+600
+10% +$362K 0.03% 552
2021
Q4 		$4.4M Buy
5,825
+872
+18% +$653K 0.03% 480
2021
Q3 		$3.69M Buy
4,953
+520
+12% +$390K 0.03% 508
2021
Q2 		$2.86M Buy
4,433
+512
+13% +$312K 0.02% 574
2021
Q1 		$2.24M Buy
3,921
+852
+28% +$505K 0.02% 614
2020
Q4 		$1.79M Buy
3,069
+182
+6% +$104K 0.02% 628
2020
Q3 		$1.49M Buy
2,887
+32
+1% +$16.2K 0.02% 631
2020
Q2 		$1.29M Buy
2,855
+1,082
+61% +$477K 0.02% 635
2020
Q1 		$622K Buy
1,773
+481
+37% +$177K 0.01% 782
2019
Q4 		$478K Buy
1,292
+434
+51% +$153K 0.01% 1024
2019
Q3 		$285K Buy
858
+83
+11% +$27.1K ﹤0.01% 1216
2019
Q2 		$242K Buy
775
+72
+10% +$21.6K ﹤0.01% 1406
2019
Q1 		$215K Buy
+703
New +$190K ﹤0.01% 1450

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

MML Investors Services's BIO Position: Q2 2026 in Review

MML Investors Services increased its Bio-Rad Laboratories Class A (BIO) stake by 23% in Q2 2026, buying an estimated $515K and bringing the position to 9,758 shares worth $2.87M. The position accounts for 0.01% of the portfolio, ranked #1313.

MML Investors Services first reported a position in BIO in Q1 2019 and has held it in 29 quarters since. The position peaked at $4.4M in Q4 2021. 190 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • MML Investors Services held 9,758 shares of Bio-Rad Laboratories Class A worth $2.87M as of Q2 2026.
  • MML Investors Services bought 1,816 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $515K.
  • Bio-Rad Laboratories Class A made up 0.01% of MML Investors Services's portfolio in Q2 2026, its #1313 holding.
  • MML Investors Services first reported a position in Bio-Rad Laboratories Class A in Q1 2019 and has held it in 29 quarters since.
  • MML Investors Services's Bio-Rad Laboratories Class A position peaked at $4.4M in Q4 2021.
  • 190 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.